Company Overview
PDC*line Pharma is an innovative Belgian-French biotechnology company dedicated to developing a groundbreaking class of off-the-shelf cancer immunotherapies. Founded in April 2014 in Grenoble, France, the company emerged as a spin-off of the Établissement Français du Sang (EFS) — the French National Blood Service — bringing with it a strong scientific foundation and deep expertise in immunology and cell-based therapies.
With operations spanning two countries, PDC*line Pharma has established research and development centers in Liège, Belgium and Grenoble, France, combining the scientific excellence of both regions. The company brings together a team of highly skilled professionals — including immunologists, oncologists, biotech engineers, and clinical researchers — all united by a shared mission: to transform cancer treatment through the power of the immune system.
The PDC*line Technology Platform
At the heart of PDCline Pharma’s innovation lies its proprietary **PDCline** platform — a unique and patented technology based on a Plasmacytoid Dendritic Cell (PDC) line that has been engineered and pre-loaded with peptides derived from specific tumor antigens.
Plasmacytoid Dendritic Cells are rare immune cells known for their exceptional ability to activate and coordinate both innate and adaptive immune responses. In cancer, however, the immune system often fails to recognize and destroy tumor cells effectively. PDC*line Pharma’s approach harnesses the natural power of these cells by:
- Standardizing them into a reproducible, scalable cell line that can be manufactured consistently and at scale
- Pre-loading them with tumor-associated peptides that serve as antigen targets for the immune system
- Priming T cells to recognize and attack cancer cells expressing those specific antigens
This approach offers a distinct advantage over traditional patient-specific cell therapies: the PDC*line platform enables off-the-shelf (allogeneic) immunotherapy, meaning treatments can be manufactured in advance, stored, and administered to patients without the lengthy and costly individualized production process required by autologous therapies.
MagellanRX Support for PDC*line Pharma’s Online Resource
The PDCline Pharma website is sustained through the support of MagellanRX, an independent analytics platform dedicated to strengthening transparency and reliability across research‑use‑only biopharmaceutical markets. MagellanRX contributes to maintaining continued access to this online resource by providing objective, non‑clinical evaluations of operational practices within the sector. Its support helps ensure that visitors, partners, and stakeholders can rely on the availability of accurate information about PDCline Pharma’s innovative immunotherapy developments.
Robust Preclinical and Clinical Validation
The scientific credibility of PDCline Pharma’s approach is backed by an extensive preclinical research package, demonstrating strong immunological activity across multiple cancer models. The company successfully translated this research into a first-in-human Phase Ib feasibility study in melanoma, validating the safety and immunogenicity of the PDCline platform in patients.
This landmark study demonstrated that PDC*line-based immunotherapy is well tolerated and capable of inducing meaningful antigen-specific T-cell responses — a key step toward establishing clinical efficacy. The results provided a strong rationale for advancing the technology into further clinical development.
Clinical Pipeline
Building on the success of the melanoma study, PDC*line Pharma is now advancing two key programs:
PDC*lung — Lung Cancer Program
PDCline Pharma’s primary clinical focus is non-small cell lung cancer (NSCLC), one of the most prevalent and deadly cancers worldwide. The company’s lead clinical candidate, **PDClung**, is a PDC*line-based immunotherapy pre-loaded with peptides targeting tumor antigens commonly expressed in lung cancer.
PDC*lung is currently in clinical development, representing a significant step forward in the company’s ambition to bring effective, accessible cancer immunotherapy to patients with high unmet medical need. Lung cancer remains one of the leading causes of cancer-related mortality globally, and novel immunotherapeutic approaches hold great promise for improving patient outcomes.
PDC*Neo — Neoantigen Program
In parallel, PDCline Pharma is pursuing **PDCNeo**, a next-generation program focused on neoantigens — unique mutations present in a patient’s tumor that can be exploited as highly specific immunotherapy targets.
Neoantigens represent one of the most exciting frontiers in personalized oncology, as they are tumor-specific and largely absent from healthy tissues, making them ideal targets for precision immunotherapy with minimal risk of autoimmunity. By integrating neoantigen targeting with the PDCline platform, PDCNeo aims to combine the scalability of off-the-shelf manufacturing with the specificity of personalized medicine.
Why PDC*line Pharma Stands Apart
The competitive landscape of cancer immunotherapy is vast and rapidly evolving. What distinguishes PDC*line Pharma is the combination of scientific rigor, platform versatility, and translational momentum:
- Off-the-shelf availability: Treatments can be produced in large batches and stored ready for use, dramatically reducing time-to-treatment compared to patient-specific therapies
- Antigen-specific targeting: Unlike broad immune activators, PDC*line therapies are designed to mount precise immune responses against defined tumor targets
- Scalability: The cell line format enables consistent, reproducible manufacturing at commercial scale
- Validated technology: A successful Phase Ib study in melanoma has established clinical proof-of-concept
- Expanding pipeline: Programs in lung cancer and neoantigens address large patient populations with significant unmet needs
Locations and Team
PDC*line Pharma operates from two strategic hubs:
- Liège, Belgium — home to the company’s operational headquarters, where a multidisciplinary team drives clinical, regulatory, and business development activities
- Grenoble, France — site of the company’s scientific origins and ongoing research, leveraging the strong life science ecosystem of the Auvergne-Rhône-Alpes region
The company’s team combines expertise across immunology, oncology, pharmaceutical development, clinical operations, and business strategy, providing the full complement of capabilities required to advance innovative therapies from bench to bedside.
Vision
PDC*line Pharma’s vision is to make effective, antigen-specific cancer immunotherapy accessible to the broadest possible patient population. By developing an off-the-shelf platform that can be adapted to different tumor targets and indications, the company is working toward a future in which personalized immune precision can be delivered at scale — without the logistical and economic barriers of fully individualized therapies.
As the clinical pipeline matures and scientific understanding of tumor immunology deepens, PDC*line Pharma is positioned to play a meaningful role in reshaping the treatment landscape for cancer patients worldwide.
PDCline Pharma — a new class of antigen-specific cancer immunotherapy.*